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Abstract  18 
 19 
Most research on the P450 (CYP) system in teleosts has been done on environmental 20 
factors that influence their induction. Less is known about CYP metabolism of aquaculture 21 
antibiotics. This paper outlines the impact of aquaculture antimicrobials on the piscine 22 
CYP system, with particular regard to interactions with tetracyclines, fluorokinolones, 23 
sulfonamides, berberine and chloramphenicol, as paradigms for current, potential and 24 
discontinued piscine antimicrobial drugs.  It gives an overview of literature reports and 25 
advances in the field of biological significance of the CYP in fish. Emphasis has been 26 
placed on highlighting the most significant isoforms for biotransformation of drugs, and 27 
their drug response mechanisms. The challenge is to elucidate the differences in responses 28 
of CYP enzymes in different species to antimicrobial treatment since they may have 29 
relevance for the use of antimicrobials in aquaculture, especially since drug interactions 30 
with the fish CYP may alter their distribution, metabolism, and elimination.  They can 31 
impact the metabolism of other drugs metabolized by the same system with an effect on 32 
the physiology of fish administered these antimicrobials. Also, they can affect the 33 
persistence of residues and the length of the withdrawal period. For food animals such as 34 
farmed fish, this knowledge is a fundamental biomedical goal. 35 
36 
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Introduction 37 
 38 
In farming of aquatic organisms, medications are needed to maintain animal health and 39 
manage fish populations. However, the development of therapeutic agents for the treatment 40 
of fish diseases involves long and complex processes. When compared with mammals, fish 41 
have some differences in pharmacokinetics that need to be considered. For example, 42 
differences in bioavailability of tetracycline, quinolones, and beta-lactam antimicrobials 43 
have been documented (Storey 2005). Oxytetracycline and amoxicillin are not well 44 
absorbed from the intestines of fish. The doses of these antimicrobials are generally 2 to 5 45 
times that needed to produce therapeutic systemic concentrations in mammalian species 46 
(Burka et al. 1997). Also, for several antimicrobials, the cations present in seawater inhibit 47 
their absorption from the intestine, while their pharmacokinetics is affected by water 48 
temperature as well (Burka et al. 1997; Storey 2005). As in other animals, most 49 
pharmaceuticals are metabolized by CYP enzymes in fish, which makes them of critical 50 
importance both for detoxification or formation of toxic metabolites.  51 
Drugs are usually lipophilic, which allows them to enter their site of action of target 52 
organs or tissues via cell membranes and exert their effect. As lipid soluble compounds, 53 
they are difficult to eliminate from the body. Metabolism, or biotransformation of these 54 
compounds into more polar, inactive metabolites, is generally an enzymatic process 55 
(Hildebrand et al. 1994; Bernhardt 2006). The CYP monooxygenases are a large 56 
superfamily of proteins present in most tissues. They are of central importance in 57 
detoxification or activation of a number of foreign hydrophobic compounds, including 58 
many therapeutic agents, chemical carcinogens and environmental pollutants (Nebert & 59 
Gonzales 1987). Many of these enzymes are inducible by the compounds they metabolize. 60 
This monooxygenase system perhaps has the widest-ranging spectrum of substrates, 61 
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overlapping those of most of the other metabolizing enzymes (Schenkman 1999; 62 
Guengerich 2004). They accept as substrate molecules as small as ethanol and as large as 63 
the polycyclic aromatic hydrocarbon (PAH), benzo(a)pyrene (BP) or the antibiotic 64 
erythromycin, that is, ranging in molecular weight (MW) from just about 40 to over a 1000 65 
kDa (Guengerich 1996). 66 
CYP isoforms are found in almost every phylum in which they have been sought 67 
(Heffernan & Winston 1997). Although they were originally discovered in mammalian 68 
hepatic microsomal preparations, they have subsequently been found in many organs and 69 
tissues of numerous other animals and in some plants, fungi and bacteria. CYP gene 70 
superfamily comprises over 8000 genes and pseudogenes distributed across a wide range 71 
of biological domains (Nelson 2009; Parente et al 2009). Already by 1998 there were more 72 
than 1000 CYP DNA sequences, and the problem of genetic nomenclature is becoming 73 
daunting (Nelson 1998; 2009). 74 
A better understanding of the role of each CYP in drug metabolism and drug-75 
induced toxicity is vital. At this time, however, most research on the CYP system in fish 76 
has been done on environmental factors that influence CYP induction. Much less is known 77 
about metabolism of aquaculture antibiotics by the CYP system (Snegaroff et al. 1989; 78 
Ishida 1992; Moutou et al. 1998; Vaccaro et al. 2003; Topic Popovic et al. 2007, 2012; Yu 79 
&Yang 2010; Zhou et al. 2011; Hu et al. 2012). 80 
Knowledge of the multiplicity, function and regulation of CYP forms in non-81 
mammalian and non-traditional species continues to grow in importance. Research on 82 
aquatic species monooxygenase systems expanded rapidly in the mid-1970s so that already 83 
by the late 1970s and 1980s several major reviews of microsomal CYP systems in aquatic 84 
species appeared (Bend & James 1978; Lech & Vodicnik 1984; Stegeman et al. 1984). 85 
Direct information regarding the identity of CYP forms in aquatic species is most abundant 86 
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for fish. The first CYPs purified from fish were from the elasmobranch little skate (Raja 87 
erinacea) (Bend et al. 1977). So far multiple CYP forms have been purified, partially 88 
purified or cloned from the freshwater and marine fish, mainly from rainbow trout 89 
(Onchorhynchus mykiss), perch (Perca fluviatilis), scup (Stenotomus chrysops), cod 90 
(Gadus morhua), tilapia (Oreochromis niloticus), zebrafish (Danio rerio), killifish 91 
(Fundulus heteroclitus), goldfish (Carassius auratus), stickleback (Gasterosteus 92 
aculeatus), medaka (Oryzias latipes) (Andersson & Förlin 1992; Stegeman 1995; Ueng & 93 
Ueng 1995; Gu et al. 2005; Luckenbach et al. 2005; Tseng et al. 2005; Goldstone & 94 
Stegeman 2008; Oh et al. 2009; Zanette et al. 2009; Goldstone et al. 2010; Hassanin et al. 95 
2012).  96 
The aim of this paper is to present a critical review of the impact of aquaculture 97 
antimicrobials on the piscine CYP system and to give an overview of recent literature 98 
reports and advances in the field of biological significance of the CYP enzymes in fish. 99 
 100 
  101 
CYP system in fish 102 
 103 
Although the research on mammalian CYPs continues to dominate the literature, there is a 104 
growing recognition of the biological significance of CYPs in fish. There are about 20 000 105 
species of fish, representing nearly one-half of all known vertebrate species. These species 106 
comprise 200 families, 32 orders and three classes within the subphylum Vertebrata.  They 107 
are extraordinary diverse, and inhabit virtually every niche within the world’s fresh and 108 
marine waters (Stegeman 1989). They are also a direct food source for humans as well as 109 
conveyors of toxic chemicals to human beings (Sen & Arinc 1998). 110 
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 Initially it was thought that fish lacked CYP-linked monooxygenases, but studies 111 
carried out in the late 1960s by Buhler and Rasmusson (1968) and Dewaide and Henderson 112 
(1968) showed that these enzymes were present in the livers of rainbow trout and other 113 
fish. Enzyme activities of fish hepatic microsomes were generally lower than in mammals 114 
and many fish CYPs had temperature optima of about 25ºC, explaining why they were not 115 
detected in the earlier studies where incubations at higher temperatures were employed. 116 
Subsequently, as observed in mammals, multiple CYP forms were discovered in fish, 117 
predominately localized in the liver, but also found in lower concentrations in other tissues, 118 
like kidney, gut, gall bladder, gonads, nervous tissue, endocrine cells, gills etc. (Andersson 119 
& Förlin 1992; Buhler 1995; Sarasquete & Segner 2000). 120 
 Fish hepatic microsomes exhibit typical reduced CO absorption spectra with a peak 121 
near 450 nm, and electron paramagnetic resonance characteristics with low-spin g values 122 
near 2.41, 2.25, and 1.91 typical for CYPs. Specific contents of CYPs in fish hepatic 123 
microsomes cluster between 0.2 and 0.5 nmol/mg. They range from less than 0.1 nmol/mg 124 
to nearly 2.0 nmol/mg microsomal protein. Such differences in content can occur within a 125 
single species, depending on strain, sex or chemical treatment (Andersson & Förlin 1992). 126 
Fish hepatic microsomes catalyze epoxidation, hydroxylation, dealkylation and oxidation 127 
reactions ascribed to CYP in other systems (Gillam 2007; Gillam & Hunter 2007). 128 
Substrates metabolized include many that are used to characterize CYPs in mammals, but 129 
activities found in teleosts might be catalyzed by CYP forms largely unrelated to the 130 
catalyst for the same activity in mammalian systems. Conversely, CYP forms that are 131 
structural homologues in teleosts and mammals could have different activities (Stegeman 132 
1993). One of the major differences between mammalian and fish CYPs is that some fish 133 
species have much higher constitutive levels of aryl hydrocarbon hydroxylase (AHH) than 134 
mammalian counterparts (Lee et al. 1992). CYP1B1 was found to be the major isoform 135 
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involved in AHH activity in human lymphocytes (Toide et al. 2003). Goksøyr et al. (1987) 136 
described certain characteristic features of the fish xenobiotic metabolizing systems: 137 
generally lower specific activities compared to mammals, but high capability to activate 138 
procarcinogens to reactive intermediates; high responsiveness of monooxygenase activities 139 
to the polycyclic aromatic hydrocarbons (PAH) class of inducers (3-MC, beta-140 
Naphthoflavone BNF, BP, etc.), but an apparent refractiveness to induction by the PB. In 141 
fish, CYPs have mostly been studied as catalysts for bioactivation of carcinogens and 142 
biomarkers of environmental contamination (Råbergh et al. 2000).  143 
As in the mammalian system, multiple forms of CYPs belonging to the families of 144 
CYP1A, CYP1C, CYP2B, CYP2E, CYP2M, CYP2K, CYP2R, CYP2U, CYP3A, 145 
CYP11A, CYP17, CYP19, CYP26 are found in fish (Godard et al. 2005; Parente et al. 146 
2009; Goldstone et al. 2010). Intensive research on fish CYPs rapidly reveals novel 147 
cytochromes, like cloning and characterization of CYP26 in zebrafish Lythrypnus zebra 148 
(Haque et al. 1998), CYP2N1 and CYP2N2 in killifish (Oleksiak et al. 2000), cloning of 149 
CYP1B1 in scup and plaice Pleuronectes quadrituberculatus (Godard et al. 2000; Leaver 150 
& George 2000), cloning, sequencing and tissue expression of CYP3A27 in rainbow trout 151 
(Lee et al. 1998), and many others. There are 54 CYP isoforms reported to be purified, 152 
partially purified, or cloned from aquatic species (Arinc & Sen 1999; Uno 2012). The 153 
number of fish species from which full-length coding regions of CYP1A genes have been 154 
sequenced has increased from four (rainbow trout, plaice, toadfish Opsanus beta and scup) 155 
to over a dozen, which include CYP1A sequences from tomcod Microgadus tomcod, 156 
butterflyfish Chaetodon ocellatus, sea bream Sparus aurata, sea bass Dicentrarchus 157 
labrax, Atlantic salmon Salmo salar, medaka Oryzias latipes, mummichog Fundulus 158 
heteroclitus, yellow catfish Pelteobagrus fulvidraco, crucian carp hybridized Prussian carp 159 
and killifish (Morrison et al. 1998; Uno, 2012). Zebrafish was found to have a total of 94 160 
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CYP genes, distributed among 18 gene families found also in mammals (Goldstone et al. 161 
2010). In mammals, sex, diet and age are among the factors known to influence 162 
monooxygenase systems. Marked sex differences also occur in CYP activities in fish (Gray 163 
et al. 1991; Topic Popovic et al. 2007). Moreover, there are changes in activity associated 164 
with species, strain, season, water temperature and gonadal status of fish (Goksøyr & 165 
Förlin 1992; Husøy et al. 1994). Although no detailed study is available on the influence of 166 
immunomodulating factors on the fish biotransformation system (Marionnet et al. 1998; 167 
Reynaud & Deschaux 2006), it can generally be said that disease may influence CYP 168 
activity through interference with endocrine homeostasis, impairment of intermediary 169 
metabolism, release of toxins, changes in tissue morphology and prolonged changes in 170 
energy intake (Guengerich 1996). Also, drug interactions on fish health have received 171 
considerably less attention compared to that on human health. Chemical interactions can 172 
affect biomarker responses in situations of mixed exposure to complex mixtures of 173 
environmental pollutants and drugs, which can result in misinterpretation of biomarker 174 
data. In that sense, inhibition of catabolic CYP enzyme activities (i.e. CYP1A and CYP3A) 175 
are linked to adverse outcomes in fish such as bioaccumulation of procarcinogens and 176 
estrogens, which can lead to carcinogenesis or cause endocrine disruption (Celander 2011). 177 
 178 
 179 
CYP1A1 and CYP1A2 in fish 180 
 181 
Although several isoforms have been identified in fish, CYP1A has received the 182 
most attention as the major hydrocarbon-inducible CYP. Subfamily CYP1A proteins in 183 
fish have reduced CO maxima at 447 nm, are the primary catalysts for 7-ethoxyresorufin 184 
O-deethylase  (EROD), ethoxycoumarin O-deethylase, and AHH, metabolize BP on the 185 
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benzo-ring, are strongly inhibited by α-naphthoflavone, are inducible by PAHs, and show 186 
reciprocal cross-reactivity with antibodies and to mammalian 1A1 (Stegeman 1993).  187 
Members of CYP1 family, including those belonging to CYP1A and 1B subfamilies, are 188 
known to play a prominent role in the activation of a number of environmentally-occurring 189 
procarcinogens and many drugs (Goldstone & Stegeman 2006; Goldstone et al. 2007; 190 
Parente et al. 2009).  For many years, it had been assumed that fish express only one 191 
CYP1A gene product that has been characterized as a CYP1A1 protein (Råbergh et al. 192 
2000). However, two genomic CYP1A clones were isolated in 1994 (Berndtson & Chen) 193 
from 3-MC treated rainbow trout and were characterized as CYP1A1 and CYP1A2 based 194 
on sequence homology, presence or absence of xenobiotic regulatory elements in 5’ 195 
flanking regions, and significant differences in intron sequence. Also, there are distinctions 196 
in temporal patterns of AHH and EROD induction, and disparate results regarding multiple 197 
protein or mRNA products induced in fish by common 1A1 and/or 1A2 inducers (Goksøyr 198 
& Förlin 1992; Stegeman 1993). Differences have been reported in the catalytic and 199 
immunological properties of hepatic microsomes from BNF (inducer of CYP1A1 in 200 
mammals) and isosafrole (inducer of CYP1A2 in mammals) treated trout (Buhler 1995; 201 
Buhler & Wang-Buhler 1998; Stegeman 1995). It is well established that the distinct 202 
difference between cytochromes CYP1A1 and 1A2 resides in their spin state. While 203 
CYP1A1 is a low spin heme protein, CYP1A2 exists as a high spin heme protein (Arinc & 204 
Sen 1999). Although CYP1A gene subfamily evolved early during vertebrate evolution and 205 
seems to be highly conserved across vertebrate taxa (Goldstone et al. 2007), constitutive 206 
levels and inducibility of CYP1A protein and catalytic activity exhibit a rather large 207 
variability between fish species and populations (Parente et al. 2009). Also, the position of 208 
the ancestral CYP1A locus remains a question: opposing orientations of the pufferfish and 209 
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frog CYP1A genes pose a conundrum with regard to determining whether CYP1A1 or 210 
CYP1A2 resides in the ancestral CYP1A gene locus (Goldstone & Stegeman 2006). 211 
CYP1A1 is localized in endothelial cells of heart, pillar cells of gills, kidney, 212 
hepatocytes, sinusoidal endothelium, and billiary epithelial cells of fish (Lester et al. 213 
1993). Contrary to mammals, where CYP1A shows a heterogeneous distribution 214 
throughout the hepatic parenchyma, no zonation can be observed in fish liver (Sarasquete 215 
& Segner 2000). However, the levels of the CYP1A1 protein found in livers of rainbow 216 
trout are low in fish not exposed to PAHs or halogenated aromatic compounds (Buhler & 217 
Wang-Buhler 1998). Upon immunohistochemical examination of liver sections unexposed 218 
to such inducers, the CYP1A1 was barely detectable (Buhler 1995). Relative molecular 219 
mass of CYP1A1 cross-reacting protein bands in Western blots of hepatic microsomes, 220 
probed with an anti-fish antibody, varies among the teleost species, and ranges between 54 221 
and 59 kDa. Also, a CYP1A3 gene has been isolated and sequenced from the rainbow trout 222 
(Carvan et al. 1999). Four CYP type 1 family enzymes (CYP1B, CYP1C1, CYP1C2 and 223 
CYP1D) have been isolated from diverse fish species (Uno et al. 2012). 224 
 225 
 226 
CYP3A4 in fish 227 
 228 
CYP3A is a gene subfamily composed of multiple forms of CYP3A enzymes as 229 
characterized by immunochemistry, catalytic activities, and cDNA cloning and expression. 230 
CYP3A is inducible by steroidal chemicals and by a variety of compounds, including 231 
naturally-occurring and synthetic glucocorticoids and macrolide antibiotics (Quattrochi & 232 
Guzelian 2001). Husøy et al. (1994) demonstrated organ distribution and cellular 233 
localization of cod CYP3A-like isozymes in control and BNF treated cod, analyzed by 234 
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imunohistochemistry and showed its occurrence in liver hepatocytes, respiratory epithelial 235 
cells of gills, intestinal and caecal mucosal epithelium, epithelium of renal tubules and 236 
pancreatic acinar cells.  237 
A strong similarity in the structure and catalytic function was found between trout 238 
and human CYP3A4 (Miranda et al. 1991), where polyclonal antibodies (IgG) generated 239 
against trout CYP LMC5 reacted strongly with CYP3A1 in dexamethasone-induced rat 240 
liver microsomes and with CYP3A4 in human hepatic microsomes in immunoblots. Buhler 241 
(1995) reports CYP3A4 isolation from livers of untreated trout, having a MW of 59 kDa, 242 
reduced CO maxima of 448 nm, and significant activity for the 6β-hydroxylation of 243 
testosterone and progesterone and for the N-demethylation of benzphetamine. Upon 244 
Western blot analysis, concentrations of CYP3A4 from the livers of trout were found to be 245 
32 % higher in liver microsomes from sexually mature males than in females (Buhler & 246 
Wang-Buhler, 1998). 247 
Control of CYP3A expression is thought to be mediated by the Ah (aryl-248 
hydrocarbon) receptor/ARNT pathway in zebrafish, whereas, the pregnane X receptor 249 
(PXR) is suggested to activate CYP3A expression in Atlantic salmon (Finn 2007; Uno et 250 
al. 2012). PXR regulates the expression of CYP3A isozymes, as well as other CYP 251 
isoforms, by binding as a heterodimer with the 9-cis retinoic acid receptor (Bainy 2007). 252 
PXR genes have been cloned from a variety of vertebrate species, including zebrafish 253 
(Bainy & Stegeman 2004).  However, there is a lack of knowledge of how pharmaceuticals 254 
and other xenobiotics interact with CYP3A and PXR in fish. Wassmur et al. (2010) 255 
established that the rainbow trout PXR is less responsive to prototypical PXR agonists than 256 
its mammalian counterparts and that it also responds differently to glucocorticoid receptor 257 
agonists. Since there are also species differences, in order to understand how 258 
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pharmaceuticals affect biotransformation in fish, sites of interaction on biotransformation 259 
pathways need to be characterized. 260 
 261 
 262 
Therapeutic agents and CYPs 263 
 264 
In recent years a huge progress has been achieved in CYP research and better 265 
understanding of the role of each CYP in drug metabolism and drug-induced toxicity (Lu 266 
1995; Cravedi 2002; Reynaud & Deschaux 2006; Li et al. 2008; Zanette et al. 2009; 267 
Goldstone et al. 2010; Uno et al. 2012). Drug response varies greatly across groups and 268 
individuals. This variability is due to many pharmacological factors. In phase I and phase 269 
II metabolism, this variability may be a reflection of enzyme inhibition, enzyme induction, 270 
and/or genetic differences and disease (Meyer 1994; Cozza & Armstrong 2001).  271 
 272 
 273 
Impact of aquaculture antimicrobials on the fish CYP system 274 
 275 
Many countries throughout the world, including Europe and the USA, have strictly 276 
regulated controls on use of veterinary medicines, particularly for use in food animal 277 
species, including fish. In the recent decades, the European legislation regarding veterinary 278 
pharmaceuticals has introduced restrictions of the use of medicines for the treatment of 279 
farm animals, and as a result, available veterinary medicinal products for fish are now 280 
authorized. The basic Directives of European legislation on veterinary medicinal products 281 
have been frequently and substantially amended over time. The main document regarding 282 
the availability of aquaculture medicines is the Regulation for the establishment of 283 
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maximum residue limits (CEC 1990; CR No 37/2010). Currently approved in the EU are 284 
amoxicillin, florfenicol, flumequine, oxolinic acid, oxytetracycline, sarafloxacin and 285 
sulfadiazine trimethoprim, while certain compounds, including chloramphenicol and the 286 
nitrofurans are specifically prohibited for use in food animals in Europe and in the USA. 287 
In the USA, all drugs legally used in aquaculture must be approved by the FDA's 288 
(Food and Drug Administration) Center for Veterinary Medicine (FDA/CVM). The Center 289 
defines drug ingredients, manufacturers, species, routes of delivery, dose forms, 290 
withdrawal periods, tolerances, and uses by species, including dose rates and limitations. 291 
The most common route of delivery of these legal antibiotics to fish occurs through mixing 292 
with specially formulated feed. In the USA there are currently only three FDA-approved 293 
and available antibiotic drugs for use in fish. They are oxytetracycline, ormetoprim and 294 
sulfadimethoxine, and florfenicol. FDA will sometimes allow veterinarians to prescribe the 295 
use of medicated feed for fish species other than those listed on the label. For example, 296 
oxytetracycline medicated feed approved for use in catfish, may be prescribed off label for 297 
hybrid striped bass by a licensed veterinarian (Durborow & Francis-Floyd 1996). 298 
Despite strict regulations, except via medicated feed, fish may get exposed to 299 
antimicrobial drugs via aquatic environment. Discharge from sewage treatment plants has 300 
been identified as their primary source (Lindberg et al. 2005; Smith et al. 2012). Numerous 301 
pharmaceuticals and other environmental contaminants are metabolized by CYP enzymes 302 
in fish, and therefore CYP enzymes are of critical importance both for detoxification and 303 
formation of toxic metabolites (Dorne et al. 2007; Beijer 2010). Although generally effect 304 
levels for pharmaceuticals are higher than those found in the environment (Corcoran et al. 305 
2010), the risks to wild fish populations have not been thoroughly characterized, and there 306 
has been a lack of consideration given to the likely chronic nature of exposures, or the 307 
potential mixture effects. 308 
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 309 
 310 
Interactions with tetracyclines  311 
 312 
Environmental exposure to oxytetracycline (OTC) and sulfathiazole was proven to 313 
indirectly increase the catalytic activity of aromatase, potentially through transcriptional 314 
level modulation (Ji et al. 2010). It also resulted in greater expression of CYP17, CYP19, 315 
or 3βHSD2, which play crucial role in steroidogenic pathways. Topic Popovic et al. (2012) 316 
determined responses to OTC treatment and investigated whether antibodies to known 317 
mammalian CYP forms (CYP1A1 and CYP3A4) would react with their respective CYP 318 
isoforms in fish (hybrid striped bass (Morone saxatilis male x Morone chrysops female), 319 
channel catfish (Ictalurus punctatus), and Nile tilapia). Additionally, expression of these 320 
CYPs as well as the activity of CYP1A2 and CYP3A4 was also assessed. Both goat anti-321 
rat CP1A1 and rabbit anti-human CYP3A4 showed good cross-reactivity with the three 322 
species tested in this study. Although some antibodies only recognize proteins from species 323 
closely related to the sources of the immunogen (Al-Arabi & Goksøyr 2002), the 324 
antibodies used in this work recognized epitopes from the divergent groups examined. 325 
Considerable non-specific binding was displayed, which was expected regarding the 326 
source of the primary antibodies (Topic Popovic et al. 2007). Immunological cross-327 
reactivity has previously been demonstrated between fish CYP3A and both rat CYP3A1 328 
and human CYP3A4 (Miranda et al. 1991). Also, clear, putative, OTC-related responses 329 
were found in liver and the hepatic phase I xenobiotic metabolizing enzyme system of the 330 
three different fish species in this observational study. This observational approach 331 
demonstrated species differences both in control activities and in the timing and extent of 332 
hepatic responses to OTC. Further, resorufin benzyl ether (BzRes) was proven to be a 333 
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better substrate than benzyloxy-4-trifluoromethylcoumarin (BFC) for monitoring CYP3A 334 
activities in fish. The data of the study indicated that antibiotics should also be evaluated in 335 
the target species under conditions of use. The variable effects in the response among 336 
different fish species to antibiotics in this work is a valid reason to critically use assays 337 
developed for mammals for evaluating drug response in fish. Moreover, the unique 338 
responses of CYP enzymes in different fish species to OTC treatment may have relevance 339 
for the use of other antibiotics in aquaculture.  340 
 341 
 342 
Interactions with fluorokinolones 343 
 344 
The first indications that CYP1A were involved in the metabolism of oxolinic acid were 345 
described by Ishida (1992), who treated carp (Cyprinus carpio) with polychlorinated 346 
biphenyl (PCB), a CYP 1A inducer, before the treatment with oxolinic acid. CYP1A was 347 
also responsible for difloxacin (DIF) metabolism in crucian carp liver (Fu et al. 2011) and 348 
its N-demethylation in Chinese idle (Ctenopharyngodon idellus) kidney (Yu & Yang 2009; 349 
Yu et al. 2010). After DIF treatment, CYP1A expression gradually decreased and was 350 
significantly lower than the control. CYP1A1 transcript level was down-regulated by DIF, 351 
suggesting that DIF is both the substrate and inhibitor of CYP1A.  352 
Enrofloxacin (EF) was assayed for the effect on induction of CYP1A mRNA in 353 
Atlantic tomcod (Williams et al. 1997). Pretranslational suppression of CYP1A induction 354 
was found in spawning females.  EF exhibited potent inhibition on the CYP1A-related 355 
EROD activity as well as CYP1A expressions at both protein an mRNA levels in crucian 356 
carp (Hu et al. 2012). In sea bass, EF was proven able to provoke the inactivation of the 357 
CYP3A enzyme (Vaccaro et al. 2003). A single dose of i.p. injection of 3 mg/kg of EF or 358 
16 
 
multi doses of 1 mg/kg were sufficient to cause a generalized depression of CYP activities 359 
in sea bass. EF was an effective inactivator of the erythromycin N-demethylase activity 360 
(Vaccaro et al. 2003; Hu et al. 2012), while immunoblot analysis showed a strong decrease 361 
of staining intensity of a protein band immunoreactive with anti CYP3A27. Therefore, it 362 
can be postulated that fluorokinolone-antibiotics such as EF in sea bass have an adverse 363 
reaction with the CYP enzymes and hence a strong potential to cause long-lasting 364 
interactions. Compared to OTC, oxolinic acid was better absorbed and faster excreted from 365 
the treated fish (Björklund et al. 1991). 366 
However, significant differences were noted in O-dealkylation and Western 367 
blotting responses between compounds of fluorokinolonic drug class when rainbow trout 368 
were fed medicated diets with oxolinic acid and flumequine (Moutou et al. 1998). Both 369 
oxolinic acid and flumequine effects were related to the CYP1A subfamily. The induction 370 
of day 10 post-treatment with oxolinic acid was confirmed by immunoblotting, while the 371 
lack of evidence for CYP1A induction after flumequine administration suggests that 372 
flumequine caused an activation of CYP1A, probably by protein stabilization. Also, the 373 
effects of oxolinic acid on O-dealkylation were delayed and longer-lasting compared with 374 
those of flumequine (Moutou et al. 1998). Such differences in CYP response post 375 
treatment can be explained with differences in the pharmacokinetics of oxolinic acid and 376 
flumequine in rainbow trout. 377 
 378 
 379 
Interactions with sulfonamides 380 
 381 
The antibacterial drug sulfamethoxazole did not markedly inhibit gill EROD activity of 382 
three-spined sticklebacks (Gasterosteus aculeatus) in the work of Beijer et al. (2010), 383 
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although inhibition of EROD activity by sulfamethoxazole has been reported in fish 384 
hepatocytes in vitro (Laville et al. 2004). Combination ormetoprim-sulfadimethoxine 385 
incorporated in diet was administered to summer flounder (Paralichtys dentatus) in study 386 
by Topic Popovic et al. (2007). Immunoblots of pre-treatment and treated summer flounder 387 
hepatic microsomes probed with goat anti-rat CYP1A1 antibodies exhibited specific bands 388 
in the region of 65-70 kDa. Dealkylation of the hepatic CYP1A2 marker 3-cyano-389 
ethoxycoumarin was significantly increased relative to pre-treatment fish through 10 days 390 
and returned to pre-treatment levels by post-treatment day 21. When identical samples 391 
were tested for BFC and BzRes activities, males and females yielded different curves. BFC 392 
activity was markedly higher in males, but females had higher BzRes activity, with both 393 
substrates specific for CYP3A4 enzymes. In this work (Topic Popovic et al. 2007) authors 394 
demonstrated the usefulness of mammalian antibodies for summer flounder CYP Western 395 
blotting and quantified CYP1A2 and 3A4 metabolism by modifying kits developed for 396 
mammalian microsomes, which could facilitate future work on piscine hepatic 397 
microsomes. As an observational study with no concurrent, untreated fish at the post-398 
treatment sampling times, inferences were limited to comparisons with pre-treatment fish 399 
and over sampling times.  While CYP1A1 and CYP3A4 enzyme activities exhibited sharp 400 
increases and decreases through post-treatment day 10, activities for both isozymes 401 
returned to pre-treatment levels by post-treatment day 21.  Considering the age of the 402 
summer flounder used and the relatively short observational period, it is unlikely that the 403 
extent of fluctuations seen in enzyme activity, 50 to 100 percent, was due to normal, 404 
possibly confounding physiological factors.  Further, these temporal perturbations in CYP 405 
enzyme activity correlate strongly with the presence of potentiated sulfonamide residues 406 
found in summer flounder (Kosoff et al. 2007).  Thus, as has been demonstrated repeatedly 407 
in mammalian systems, therapeutic compounds that are not substrates of phase I oxidative 408 
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enzymes have the potential for interfering with the biotransformation of other therapeutic 409 
compounds or environmental chemicals.  For food animals such as the summer flounder, 410 
the implications of this prospect impact the withdrawal time of additional therapeutics or 411 
the presence of environmental contaminants in edible tissues.     412 
 413 
 414 
Interactions with berberine and chloramphenicol  415 
 416 
Berberine, a quaternary isoquinoline alkaloid, could enhance the serum bactericidal 417 
activity in fish by activating the complement system, giving it a potential for prevention or 418 
treatment of fish diseases (Ji et al. 2012), and has long been considered as an antibiotic 419 
candidate for controlling systemic bacterial infections in fish, especially in synergistic 420 
action with enrofloxacin (Zhang et al, 2009). In the work of Zhou et al. (2011) berberine 421 
acted as a potent inhibitor of crucian carp CYP1A, reducing not only CYP1A mRNA 422 
expression in a dose-dependent manner, but also directly inhibiting this enzyme 423 
competitively. Also, high berberine doses inhibited CYP3A through the downregulation of 424 
its expression at the both mRNA and protein level. The authors compared the identity of 425 
this crucian carp CYP1A isoform with those of human at the amino acid level and found 426 
that it had a stronger identity with human CYP1A2 than CYP1A1. Hence, the mechanisms 427 
underlying the effects of berberine on crucian carp CYP1A isoform and human CYP1A 428 
expressions may be quite different. 429 
Chloramphenicol (CP), a broad spectrum antibiotic, has previously been used for 430 
treatment of fish bacterial diseases, particularly furunculosis and diseases caused by 431 
pseudomonads (Snieszko 1954). In trout liver cells the biotransformation of labeled CP, 432 
CP-glucuronide, was found to be the major metabolite, along with the CP-base, CP-alcohol 433 
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and CP-oxamic acid, while the metabolic rate of the 3H-CP reached 0.2 nmol/hr/106 trout 434 
hepatocytes (Cravedi & Baradat 1991). Snegaroff et al. (1989) measured interactions 435 
between chloramphenicol and monooxygenases by measuring aldrin epoxidase (AE) and 436 
found that the AE activities in trout liver were severely inhibited under higher 437 
concentrations, but not inhibited by chloramphenicol under concentrations below a certain 438 
threshold. Chloramphenicol was also shown to have an inhibitory effect on the hepatic 439 
EROD activities in rainbow trout, both in vivo and in vitro (Snegaroff et al. 1989), 440 
however, it had very little or no inhibitory effect on trout lauric acid (ω-1)-hydroxylase and 441 
dimethylbenz[a]anthracene hydroxylase activities (Miranda et al. 1998). Understanding the 442 
inhibition mechanism would minimize the selection of drugs that could either inhibit or 443 
destroy CYPs. Decreased CYP levels could result in unacceptably high plasma drug level 444 
and long drug half-life. 445 
 446 
 447 
Conclusion 448 
 449 
There is an array of antimicrobial drugs evaluated for the effects on CYPs in fish. While 450 
the majority of these compounds are regularly detected in the aquatic environment from 451 
human-use and agriculture, some are utilized in aquaculture for treatment of fish diseases. 452 
However, drug interaction studies are lacking outside of mammalian species and not 453 
enough is known about the effects of aquaculture antibiotics on the piscine CYP system. 454 
Although fish CYPs are likely inducible by mammalian inducers, the specific isoforms 455 
responsive to such inductions are still unclear, and information on fish CYP induction 456 
potential and catalytic activity is often inferred from mammalian systems, assuming similar 457 
patterns. Since both CYP1A1 and CYP3A4 have become important markers of chemical 458 
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exposure in many species including fish, perturbations of the activities of these enzymes 459 
may have consequences in the metabolism of antimicrobial drugs, especially CYP3A4, 460 
arguably the most important enzyme involved in the metabolism of xenobiotics.   461 
Antimicrobial drugs must be evaluated extensively in the target organism. Drug 462 
interactions with the fish CYPs may alter their distribution and metabolism, as well as 463 
elimination.  They can impact the metabolism of other drugs and xenobiotics metabolized 464 
by the same system with an effect on the physiology of fish administered these 465 
antimicrobials. The differences in responses of CYP enzymes in different fish species to 466 
antimicrobial treatment may have relevance for the use of antimicrobials in aquaculture. 467 
The variable effects in the response among different fish species to antimicrobial drugs is a 468 
valid reason to critically use assays developed for mammals for evaluating drug response 469 
in various fishes. Also, the use of CYP antibodies across phyla can be of value if caution is 470 
exercised in the interpretation. Substrates developed for use in mammalian systems have 471 
been assayed in fish, and are useful for CYP-mediated functional comparison between 472 
mammalian and fish species. Standardized protocols for drug impact on fish CYPs will 473 
facilitate those studies and standards will be necessary for the future application on 474 
teleosts.  475 
Since the metabolism of aquaculture antimicrobials by the CYP enzymes could also 476 
determine the metabolism of other xenobiotics and endogenous compounds, along with 477 
persistence of residues and the length of the withdrawal period before fish being apt for 478 
human consumption, and taking into consideration other challenges and concerns 479 
regarding drug approval/administration/dosing/metabolism, impact of antimicrobial drugs 480 
on piscine CYPs requires further in-depth studies, equal to their mammalian counterparts.  481 
 482 
 483 
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